Ark Clinical Research | Long Beach, CA
Status and phase
Conditions
Treatments
About
The purpose of the Phase 1 Part of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1403 and mRNA-1405 in healthy adult participants 18 to 49 years of age and 60 to 80 years of age. The purpose of the Phase 2 Part of the study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1403 in healthy adult participants 18 to 80 years of age.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Key Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
1,285 participants in 15 patient groups, including a placebo group
Loading...
Central trial contact
Moderna Clinical Trials Support Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal